Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

OTHER 10INDUSTRY 3NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasm Metastasis 2Carcinoma 2Adenocarcinoma 2Sarcoma, Ewing 1Gastrointestinal Stromal Tumors 1Colonic Neoplasms 1

Interventions

Fluorouracil 20Leucovorin 18Oxaliplatin 11Irinotecan 10Capecitabine 6Bevacizumab 5Cetuximab 4Levamisole 3Celecoxib 3cediranib 2Watchful Waiting 2Tegafur 2Surveys and Questionnaires 2Psychiatric Rehabilitation 2Folfox protocol 2Counseling 2Cisplatin 2tumor necrosis factor-alpha, CNGRC fusion protein, human 1tipifarnib 1regorafenib 1pertuzumab 1olaparib 1mercaptoundecahydrododecaborate 1gevokizumab 1eniluracil 1cemiplimab 1brivanib 1alpha-Tocopherol 1Vitamin E 1Uracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Colonic Neoplasms × regorafenib × Clear all
NCT02664077 2022-04-14

ARGO

NSABP Foundation Inc

Phase 3 Terminated
34 enrolled
Gastrointestinal

Colonic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡